FDA Grants Approval for Atropine Sulfate ANDA219013 by Edenbridge Pharmaceuticals
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219013 for Atropine Sulfate submitted by Edenbridge Pharmaceuticals.
Company
Pharmaceutical intelligence for Edenbridge Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.